CEO & Co-Founder Opportunity | Deeptech BioEngineering | Drug Discovery
Are you looking for an entrepreneurial opportunity at the intersection of microfluidics, advanced in-vitro models and drug discovery, with the chance to build a high-impact deep-tech spin-off?
OGYX is developing a cost-effective, robust and user-friendly microfluidic Organ-on-a-Chip platform designed for high-throughput in-vitro assays in research, drug development and toxicology. Backed by Leitat and a strong technical team, the project is now seeking an entrepreneurial CEO to lead the creation of the spin-off and drive its commercial and strategic development.
As CEO & Co-Founder, you will lead the venture-building journey together with the scientific and technical team, shaping the business model, early market traction and fundraising strategy of a company with the potential to become a preferred platform provider in the Organ-on-a-Chip market.
About OGYX
Drug discovery still relies heavily on animal models and conventional in-vitro systems,
both of which often fail to accurately replicate human physiology. This results in poor predictive power, major development inefficiencies and growing ethical and regulatory pressure to reduce animal testing.
Organ-on-a-Chip technologies offer a promising alternative, but current solutions face important limitations: they often compromise essential 2D/3D co-culture features, require peripheral equipment, or are not well suited for multiplexed high-throughput readouts and scalable production.
OGYX addresses this challenge with a microfluidic OoC plate designed for high-throughput screening, compatible with 2D/3D co-cultures and organoids, and readable with standard multi-well plate readers. Its design combines biological relevance, usability and manufacturability in a single platform.